British Columbia Cancer Agency

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026) Zwimpfer TA, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, et al. Journal article SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival (2025) Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching P, Bardia A, Chia S, et al. Journal article Reirradiation clinical practice in gastrointestinal abdominal malignancies: an international reirradiation collaborative group (ReCOG) systematic review (2025) Malik NH, Plastaras JP, Corradini S, Dawson LA, Hawkins MA, Salerno KE, Mayo CS, et al. Journal article, Review article Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial (2025) Fasching P, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, et al. Journal article Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies (2025) Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, et al. Journal article, Letter First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. (2025) Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, et al. Journal article Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial (2025) Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, et al. Journal article BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated with Endocrine Therapy with or Without Palbociclib: A Secondary PENELOPE-B Study Analysis (2025) Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, et al. Journal article Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping (2025) Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, et al. Journal article